



**18th
ICML**

International
Conference
on Malignant
Lymphoma
Lugano

**17–21
June
2025**

CONFERENCE SCHEDULE (updated on 30 April 2025)

Tuesday, 17 June 2025

- 10:00 – 16:30 **CLOSED WORKSHOP (in-person event - by invitation only)**
*Polivalente room,
East Campus USI*
Genetics of diffuse large B cell lymphoma: toward improved diagnosis, outcome prediction and therapeutic targeting
Co-chairs: Francesco Bertoni, Bellinzona, CH, Franco Cavalli, Bellinzona, CH and Riccardo Dalla-Favera, New York, NY, US
*Organized with the support of: American Association for Cancer Research – AACR
European School of Oncology Foundation - ESOF
European Society for Medical Oncology - ESMO*
- 14:00 – 17:00 **LYMPHOMA RADIOTHERAPY WORKSHOP**
Cinema Corso
New frontiers in radiation therapy of haematological malignancies - augmenting the effect of systemic therapy
Organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG
- 14:00–15:30 Part 1: Radiation therapy and CAR-T-cell therapy, an update
Chairs: David C. Hodgson, Toronto ON, CA and Joachim Yahalom, New York, NY, US
- 14:00 Bridging, debulking and/or priming, what is/are the mechanisms underlying the effect of radiation therapy in CAR-T-cell therapy?
Carl DeSelm, St. Louis, MO, US
- 14:15 Update on the UK experience (RESTART protocol)
Andrea Kuhn, London, UK
- 14:30 Update on the MD Anderson experience
Bouthaina S. Dabaja, Houston, TX, US
- 14:45 Effective cytoreduction by RT prior to CAR-T salvage in aggressive B cell lymphomas
Harper Hubbeling, New York, NY, US
- 15:00 Update on the Toronto experience
Danielle Rodin, Toronto ON, CA

15:15	ILROG on the Edge: Walking the “Fine Guideline” For RT-CART John Plastaras, Philadelphia, PA, US, on behalf of the consortium
15:30	BREAK
15:45-17:00	Part 2: New aspects in combining systemic therapy and radiation therapy in the management of haematological malignancies Chairs: Michael MacManus, Melbourne VIC, AU and Joanna Yang, St. Louis, MO, US
15:45	Managing the partial response – radiation therapy, salvage chemotherapy, CAR-T-cell therapy, or monitoring Andrea Ng, Boston, MA, US
16:00	Indications for radiotherapy in PET-negative advanced DLBCL George Mikhaeel, London, UK
16:15-16:45	Global perspective – extranodal NK/T-cell lymphoma
16:15	Which systemic regimen should be used today? Qingqing Cai, Guangzhou, CN
16:30	Radiation doses and volumes in early stages with modern systemic therapy Shunan Qi, Beijing, CN
16:45-17:00	Panel discussion: Combining systemic therapy and radiation therapy in these clinical situations All speakers

08:30 – 09:15	“MEET THE PROFESSOR” SESSIONS 5 parallel sessions	
<i>Room A</i>	Classic Hodgkin lymphoma Andrew M. Evens, New Brunswick, NJ, US	EB5
<i>Room B</i>	Diffuse large B-cell lymphoma and high-grade lymphoma Grzegorz S. Nowakowski, Rochester, MN, US	N/A
<i>Cinema Corso</i>	Multiple myeloma Francesca Gay, Turin, IT	EB6
<i>Auditorium, West Campus USI</i>	Marginal zone lymphomas Sonali M. Smith, Chicago, IL, US	EB11
<i>Polivalente room, East Campus USI</i>	Follicular lymphoma Jessica Okosun, London, UK	EB10
09:30 – 10:15	“MEET THE PROFESSOR” SESSIONS 5 parallel sessions	
<i>Room A</i>	Nodular lymphocyte-predominant Hodgkin lymphoma Diagnosis - Elias Campo, Barcelona, ES Management - Peter Borchmann, Cologne, DE	EB2
<i>Room B</i>	CLL and Richter Matthew S. Davids, Boston, MA, US	EB3
<i>Cinema Corso</i>	Multiple myeloma (repetition) Francesca Gay, Turin, IT	EB6
<i>Auditorium, West Campus USI</i>	T-cell redirecting therapies Gloria Iacoboni, Barcelona, ES	EB7
<i>Polivalente room, East Campus USI</i>	Waldenström Macroglobulinemia Steven P. Treon, Boston, MA, US	EB12

10:35 – 12:00	EDUCATIONAL SYMPOSIA 2 parallel sessions	
<i>Room A, broadcast in Cinema Corso</i>	Mantle cell lymphoma Chair: Martin Dreyling, Munich, DE	
10:35	The biomarkers we need Simone Ferrero, Turin, IT	EB13
11:00	First line therapy: BTKi? Transplant? Martin Dreyling, Munich, DE	EB14
11:25	Relapsed disease: sequencing Eva Giné Soca, Barcelona, ES	EB15
11:50	Panel discussion	
<i>Room B, broadcast in Marquee Parco Ciani, Auditorium, Polivalente room</i>	Clonal precursors Chair: Markus Manz, Zurich, CH	
10:35	Clonal hematopoietic stem cell precursors Markus Manz, Zurich, CH	EB16
10:55	Clonal T-cell precursors Claire Dearden, London, UK	EB17
11:15	Clonal B-cell precursors Paolo Ghia, Milan, IT	EB18
11:35	Clonal plasma cell precursors Angela Dispenzieri, Rochester, MN, US	EB19
11:55	Panel discussion	
13:00 – 14:00	OPENING OF THE CONFERENCE WELCOME AND INTRODUCTORY REMARKS Franco Cavalli, Bellinzona, CH	
<i>Room A, broadcast in all rooms</i>		

HENRY KAPLAN MEMORIAL LECTURES**Abstract nr.**

Laudatio: Franco Cavalli, Bellinzona, CH

Equal parts dreams, luck and madness: conjuring a new future for lymphoma therapy
Bruce D. Cheson, Bethesda, MD, US 001

The road to disease discovery: a personal journey
Elaine S. Jaffe, Bethesda, MD, US 002

14:00 – 15:15

PLENARY SESSION

*Room A,
broadcast in all
rooms*

Co-chairs: Franco Cavalli, Bellinzona, CH and Catherine Thieblemont, Paris, FR

14:00 **Large B-cell Lymphoma Microenvironment Archetype Profiles (LymphoMAPs) identify subgroups with greatest benefit from CD19 CAR T-cell therapy** 005

David A. Russler-Germain, St. Louis, US

14:15 Discussant: Stephen M. Ansell, Rochester, MN, US

14:25 **Feasibility of ctDNA and PET guided therapy in untreated DLBCL. Preliminary results of the SAKK 38/19 phase II trial** 006

Anastasios Stathis, Bellinzona, CH

14:40 Discussant: Mark Roschewski, Bethesda, MD, US

14:50 **Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase III POLARGO trial** 007

Juan-Manuel Sancho, Barcelona, ES

15:05 Discussant: Laurie H. Sehn, Vancouver BC, CA

15:45 – 16:45

AACR – ICML JOINT SESSION

*Room A,
broadcast in all
rooms*

The role of artificial intelligence in oncology

Co-chairs: Francesco Bertoni, Bellinzona, CH and Margaret Foti, Philadelphia, PA, US

15:45 The role of AI in pathologic diagnosis 008
Pierre Brousset, Toulouse, FR

16:05 The role of AI in imaging readings 009
Irene Buvat, Paris, FR

16 :25 The role of AI in clinical trial design 010
Stefan Michiels, Villejuif, FR

17:00 – 18:00

“FOCUS ON...” SESSIONS

5 parallel sessions

Room A

FOLLICULAR LYMPHOMA

Co-chairs: Sonali M. Smith, Chicago, IL, US and TBC

- 17:00 **Follicular lymphoma epidemiology and outcomes in England 2014-2021: preliminary analysis from the UNCOVER Study Group** 096
Kim M. Linton, Manchester, UK
- 17:10 **Mutation signatures involving epigenetic modifiers predict follicular lymphoma response to radiotherapy** 097
N. Ari Wijetunga, Chapel Hill NC, US
- 17:20 **Fludarabine, cyclophosphamide and rituximab (FCR) as initial treatment for high tumour burden follicular lymphoma: Final results of the UK phase III PACIFICO trial** 098
Andrew Petitt, Liverpool, UK
- 17:30 **Fixed duration subcutaneous mosunetuzumab in patients with previously untreated high-tumor burden follicular lymphoma: interim results from the Phase II MorningSun study** 099
L. Elizabeth Budde, Duarte, CA, US
- 17:40 **Tazemetostat in Combination with R-CHOP in Patients with high-risk, frontline Follicular Lymphoma (Epi-RCHOP) in need of therapy: a phase II study from the LYSA** 100
Loic Ysebaert, Toulouse, FR
- 17:50 **Valemetostat monotherapy in patients with relapsed or refractory follicular lymphoma: primary results of the phase 2 VALYM study from the LYSA group** 101
Emmanuel Bachy, Lyon, FR

*Room B,
broadcast in
Marquee Parco
Ciani*

NEW CELLULAR THERAPIES

Co-chairs: Gloria Iacoboni, Barcelona, ES and Federico Simonetta, Geneva, CH

- 17:00 **High CR and MRD Negativity Rates With GLPG5101, a Fresh, Stem-Like, Early Memory CD19 CAR T With 7-Day Vein-to-Vein Time: Full Results From ATALANTA-1 Cohort 3 (iNHL)** 102
Marie José Kersten, Amsterdam, NL
- 17:10 **A Phase 1 Study of KITE-363 Anti-CD19/CD20 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory (R/R) B-Cell Lymphoma** 103
Saurabh Dahiya, Stanford, CA, US

17:20	A GLOBAL PHASE 1B STUDY OF JNJ-90014496, A CD19/CD20 BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) Krish Patel, Nashville, TN, US	104
17:30	Interim Results of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel in Relapsed/Refractory Diffuse Large B Cell Lymphoma Nirav N. Shah, Milwaukee, WI, US	105
17:40	LYL314, a CD19/CD20 CAR T-cell candidate enriched for CD62L+ stem-like cells, achieves high rates of durable complete responses in R/R large B-cell lymphoma Akil Merchant, Los Angeles, CA, US	106
17:50	Results from the dose-finding part of LuminICE-203 Phase 2 study: Acimtamig (AFM13) in combination with AlloNK (AB-101) in patients with relapsed / refractory Hodgkin lymphoma Joseph Maakaron, Minneapolis, MN, US	107
<i>Cinema Corso</i>	ONGOING TRIALS Co-chairs: Kerry J. Savage, Vancouver BC, CA and Grzegorz S. Nowakowski, Rochester, MN, US	
17:00	A Phase 3 Trial of Obinutuzumab and Venetoclax With or Without Acalabrutinib in Patients with High Risk Chronic Lymphocytic Leukemia: CLL16 trial of the GCLLSG Nadine Kutsch, Cologne, DE	OT1
17:10	CLL18/MOIRAI trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in treatment-naive CLL/SLL Paula Cramer, Cologne, DE	OT2
17:20	BGB-11417-302, A Phase 3, Randomized, Double-Blind Study of Sonrotoclax (BGB-11417) + Zanubrutinib Vs Placebo + Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma Martin Dreyling, Munich, DE	OT3
17:30	GOLSEEK-1: A Phase 3, Double-Blind, Randomized Study of Golcadomide + R-CHOP vs Placebo + R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma Grzegorz S. Nowakowski, Rochester, MN, US	OT4
17:40	GUIDANCE-02: A multi-center randomized phase 3 study of genetic subtype-guided immunochemotherapy in diffuse large B-cell lymphoma Weili Zhao, Shanghai, CN	OT5
17:50	AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy to Immuno-oncology for Children & Adults with Newly Diagnosed Stage I/II Hodgkin	OT6

Lymphoma

Jennifer Seelisch, London ON, CA

Auditorium,

West Campus USI

RADIATION THERAPY

Co-chairs: Bouthaina S. Dabaja, Houston, TX, US and Lena Specht, Copenhagen, DK

- 17:00 **Local control with response-adapted very low dose radiotherapy (RA-VLDRT) of 4 Gy for indolent non-Hodgkin lymphoma** 108
Nikhil P. Mankuzhy, New York, NY, US
- 17:10 **Ultra-low dose radiotherapy (ULDR) (4Gy) for indolent orbital adnexal lymphomas (IOAL): An International Lymphoma Radiation Oncology Group study** 109
Lilly Shen, Melbourne VIC, AU
- 17:20 **High PFS with low infield recurrences after low dose radiotherapy and Obinutuzumab in early stage nodal follicular lymphoma: final results of the GAZAI study (GLA 2018-3)** 110
Klaus Herfarth, Heidelberg, DE
- 17:30 **BOOM-BOOM Radiation Prior to Lisocabtagene Maraleucel Is Feasible and Contributes to High Complete Response Rates For Aggressive B-cell Non-Hodgkin Lymphoma** 111
Christopher D'Angelo, Omaha, NE, US
- 17:40 **Phase I Study of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas** 112
Brandon S. Imber, New York, NY, US
- 17:50 **Can Salvage Radiotherapy Achieve Durable Local Control in Relapsed/Refractory Large B-Cell Lymphoma Post-CAR T Failure?** 113
Hazim Ababneh, Boston, MA, US

Polivalente room,

East Campus USI

EXPERIMENTAL THERAPEUTICS

Co-chairs: Georg Lenz, Münster, DE and Patrizia Mondello, Rochester, MN, US

- 17:00 **Systematic investigation of disease- and genotype-specific vulnerabilities in primary blood cancer using high-throughput ex vivo drug screening** 114
Kevin D. Hofer, Zurich, CH
- 17:10 **The BTK degrader BGB-16673 and the BCL2 inhibitor sonrotoclax shows anti-tumor activity as single agents and in combination in marginal zone lymphoma models** 115
Alberto J. Arribas, Bellinzona, CH
- 17:20 **The Toll-Like Receptor 7/8 Pathway Has Prognostic Significance and is a Therapeutic Target in CNS Lymphomas** 116
James L. Rubenstein, San Francisco, CA, US

17:30	DUAL TARGETING CD30/PDL-1 CAR-T CELLS OUTPERFORMS CD30 CAR-T CELLS IN A NEWLY DEVELOPED IMMUNOSUPPRESSIVE 2D CELLULAR MODEL MIMICKING CLASSIC HL MICROENVIRONMENT Vincenzo M. Perriello, Perugia, IT	117
17:40	CDK7 enables the functional crosstalk between lymphoma and microenvironment (TME) cells in peripheral T-cell lymphoma (PTCL) Khoulood Kouidri, New York, NY, US	118
17:50	LIS22: An Effective Multimodal Polyclonal Antibody Targeting T-Cell Malignancies Firas Bassissi, Nantes, FR	119

08 :15 – 09 :00	“MEET THE PROFESSOR” SESSIONS 5 parallel sessions	
<i>Room A</i>	Non-clonal lymphoproliferative diseases Diagnosis - Stefan Dirnhofer, Basel, CH Management of Castleman disease - Angela Dispenzieri, Rochester, MN, US	EB4
<i>Room B</i>	Diffuse large B-cell lymphoma and high-grade lymphoma (repetition) Grzegorz S. Nowakowski, Rochester, MN, US	N/A
<i>Cinema Corso</i>	Peripheral T-cell lymphoma Won Seog Kim, Seoul, KR	EB8
<i>Auditorium, West Campus USI</i>	Waldenström Macroglobulinemia (repetition) Steven P. Treon, Boston, MA, US	EB12
<i>Polivalente room, East Campus USI</i>	Marginal zone lymphomas (repetition) Sonali M. Smith, Chicago, IL, US	EB11
09:15 – 10 :30	“CHALLENGING CASES DISCUSSION” SESSIONS 3 parallel sessions	
<i>Room A</i>	Aggressive B-cell lymphomas Chair: Ranjana H. Advani, Palo Alto, CA, US Presenter: Maria Cristina Piroso, Bellinzona, CH Discussants: Brad Kahl, Saint Louis, MO, US, Laurie Sehn, Vancouver BC, CA, Lena Specht, Copenhagen, DK	
<i>Cinema Corso</i>	T-cell lymphoma Chair: Won Seog Kim, Seoul, KR Presenter: Ilaria Romano, Bellinzona, CH Discussants: Won Seog Kim, Seoul, KR, Kerry J. Savage, Vancouver BC, CA, Pier Luigi Zinzani, Bologna, IT	
<i>Auditorium, West Campus USI</i>	Paediatric lymphomas Panelists: Amos Burke, Birmingham, UK, Francesco Ceppi, Lausanne, CH, Wilhelm Wössmann, Hamburg, DE	

<i>09:15 – 10:30</i> <i>Room B,</i> <i>Broadcast in</i> <i>Marquee Parco</i> <i>Ciani</i>	SESSION 1: IMAGING AND RADIOMICS Co-chairs: Anne-Ségolène Cottreau, Paris, FR and TBC	<u>Abstract nr.</u>
09:15	Predicting 2-Year Time to Progression in Diffuse Large B-Cell Lymphoma Using Artificial Intelligence on Whole-Body PET Scans Maria C. Ferrandez Ferrandez, Amsterdam NL	011
09:30	Imaging Biomarkers for the Definition of Response in the GHSG HD18, GHSG HD21 and LYSA AHL2011 Trials for Advanced-stage Hodgkin Lymphoma Justin Ferdinandus, Cologne, DE	012
09:45	Prognostic Value of the Combination of Radiomics Parameters Measured on Baseline FDG PET/CT in Primary Mediastinal B-Cell Lymphoma Pierre Decazes, Rouen, FR	013
10:00	Performance of baseline and end-of-treatment FDG-PET radiomics in patients with Peripheral T-Cell Lymphoma: Data from International Prospective T-Cell Project 2.0 Tetiana Skrypets, Bari, IT	014
10:15	Early PET response predicts risk of relapse after 2L axi-cel in large B-cell lymphoma Andrea Kuhn, London, UK	015
<i>09:15 – 10:30</i> <i>Polivalente room,</i> <i>Campus Est USI</i>	SESSION 2: BASIC AND TRANSLATIONAL RESEARCH LYMPHOMA EPIGENETICS Co-chairs: Ari M. Melnick, New York, NY, US and TBC	
09:15	Epigenetic mechanisms and therapy for B-cell lymphomas Ari M. Melnick, New York, NY, US	016
09:35	Super-enhancer hypermutation in DLBCL: targeting the glucocorticoid receptor pathway Riccardo Dalla-Favera, New York, NY, US	017
09:55	Epigenetic vulnerabilities: pre-clinical and clinical evidences Franck Morschhauser, Lille, FR	018
10:15	Multi-omic Profiling of Dark Zone Lymphomas Uncovers Dysregulated Gene Regulatory Networks Reflecting DZ-LZ B-cell Transition Dynamics Amos Fong, Vancouver BC, CA	019

11 :00 – 12 :00	SESSION 3: HODGKIN LYMPHOMA FROM CHILDREN TO ADULTS	
<i>Room A, broadcast in Room B, Marquee Parco Ciani, Cinema Corso, Auditorium</i>	Co-chairs: Ranjana H. Advani, Palo Alto, CA, US and Wilhelm Wössmann, Hamburg, DE	
11 :00	Impact of EBV Status and Histology on Outcomes with Nivolumab-AVD versus Bv-AVD in Patients Enrolled on SWOG S1826 Sairah Ahmed, Houston, TX, US	020
11 :15	Prognostic Value of Circulating Tumor DNA in Patients with Advanced Stage Classic Hodgkin Lymphoma Treated on SWOG S1826 Alex F. Herrera, Duarte, CA, US	021
11 :30	Prognostic value of baseline total metabolic tumor volume (TMTV) and tumor spread (Dmax) in advanced Hodgkin lymphoma: Ancillary study of the AHL2011 trial Cédric Rossi, Dijon, FR	022
11 :45	Radiotherapy improves progression-free survival for stage IA NPLHL: A retrospective report from the Global nLPHL One Working Group (GLOW) Jamie E. Flerlage, Rochester, NY, US	023
11 :00 – 12 :00	"FOCUS ON..." SESSION	
<i>Polivalente room, East Campus USI</i>	CROSS-CUTTING TOPICS Co-chairs: Carlos Chiattono, Sao Paulo, BR and Annarita Conconi, Biella, IT	
11 :00	Detection of Intratumoral microorganisms and their impact on outcomes in untreated diffuse large B-cell lymphoma Paola Ghione, New York, NY, US	120
11 :10	Influence of health disparities (HD) on clinical outcomes in patients (pts) with diffuse large B cell lymphoma (DLBCL) in the United States Alvaro J. Alencar, Miami, FL, US	121
11 :20	Identifying Harmful Hyperinflammation in Diffuse Large B-cell Lymphoma using the OHI (Optimized HLH Inflammatory) Index - Discovery and Validation in Real-World Patients Thomas E. Witzig, Rochester, MN, US	122
11 :30	Updated Interim Results of Sonrotoclax + Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM): an All-Oral Treatment Binod Dhakal, Milwaukee, WI, US	123

11 :40	Updated Results: Ph 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with EBV+ PTLD after Rituximab+/- Chemotherapy Failure Sylvain Choquet, Paris, FR	124
11 :50	Rituximab in combination with bendamustine achieves rapid and sustained responses in anti-MAG neuropathy Damien Roosweil, Paris, FR	125
13 :00 – 13 :45 <i>Room A, broadcast in all rooms</i>	GIANNI BONADONNA MEMORIAL LECTURE Supported by the European School of Oncology Foundation – ESOF Chair: Franco Cavalli, Bellinzona, CH Laudatio: Riccardo Dalla-Favera, New York, NY, US	
	Molecular classification of aggressive B-cell lymphomas David Scott, Vancouver BC, CA	003
14 :00 – 15 :30	PARALLEL SESSIONS 3 parallel sessions	
<i>Room A, broadcast in Room B, Marquee Parco Ciani, Cinema Corso</i>	SESSION 4: FOLLICULAR LYMPHOMA Co-chairs: Jonathan W. Friedberg, Rochester, NY, US and Judith Trotman, Sydney NSW, AU	
14 :00	Unveiling Follicular Lymphoma Heterogeneity: A Single-Cell Atlas Reveals Prognostic Cellular Ecosystems and Novel Biomarkers Associated with High-Risk Sandrine Roulland, Marseille, FR	024
14 :15	Response-adapted very low dose radiotherapy (RA-VLDRT) for potentially curable indolent non-Hodgkin lymphoma Nikhil P. Mankuzhy, New York, NY, US	025
14 :30	Ibrutinib-Rituximab Versus Placebo-Rituximab in Patients With Previously Untreated Follicular Lymphoma (FL): Primary Analysis of the Phase 3 PERSPECTIVE Study David Belada, Hradec Králové, CZ	026
14 :45	Mosunetuzumab (mosun) Produces Durable Benefit in Patients (pts) with Newly Diagnosed Follicular Lymphoma (FL): Extended Follow up of the MITHIC-FL1 Trial Lorenzo Falchi, New York, NY, US	027
15 :00	Outcomes From the Phase 3 inMIND Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and Rituximab (R) for Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Laurie H. Sehn, Vancouver BC, CA	028

15:15	A Comparative Analysis of Histologic Transformation of Follicular Lymphoma at Diagnosis (composite lymphoma) and Sequentially Transformed Follicular Lymphoma Carla Casulo, Rochester, NY, US	029
14:00 – 16:35	SESSION 5: PEDIATRIC LYMPHOMAS Co-chairs: Francesco Ceppi, Lausanne, CH and Wilhelm Wössmann, Hamburg, DE <i>Auditorium, West Campus USI</i>	
14:00	Exosomes and miRs in childhood NHL and Hodgkin's lymphoma Lara Mussolin, Padua, IT	030
14:25	Relapsed/refractory mature B-NHL in children and adolescents Amos Burke, Birmingham, UK	031
14:50	Metabolic-only response assessment allows radiation omission for majority with classical Hodgkin lymphoma and maintains excellent outcomes: a PHC phase 2 study cHOD17 Jamie E. Flerlage, Rochester, NY, US	032
15:00	Glofitamab plus R-ICE or as monotherapy in children and adolescents with relapsed/refractory B-cell non-Hodgkin lymphoma: updated analysis from the iMATRIX-GLO study Veronique Minard-Colin, Villejuif, FR	033
15:10	Targeted Immunotherapy in Children, Adolescents, and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma, a single center experience Mitchell S. Cairo, New York, NY, US	034
15:20	BREAK	
15:45	Second Malignant Neoplasm Risk after Mediastinal Radiotherapy for Pediatric Hodgkin Lymphoma on Children's Oncology Group AHOD1331 Sarah Allison Milgrom, Aurora, CO, US	035
15:55	Frequency of fusion genes and their clinical impacts in Chinese pediatric patients with T-cell lymphoblastic lymphoma Yonghong Zhang, Beijing, CN	036
16:05	Patterns of fatigue in high-risk pediatric Hodgkin lymphoma (HL) treated with Pediatric Hodgkin Consortium (PHC) brentuximab vedotin-containing European-derived regimens Angela M. Feraco, Boston, MA, US	037
16:15	Clinical analysis of 53 cases of relapsed or refractory childhood ALK + anaplastic large cell lymphoma Kai Wang, Beijing, CN	038

16:25	Impact of Time of Onset on Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes: Results from a Prospective/Retrospective Multicenter Study Lianna Jean Marks, Palo Alto, CA, US	039
14 :00 - 15 :30	SESSION 6: LIQUID BIOPSY FOR RESPONSE ASSESSMENT Co-chairs: Mark Roschewski, Bethesda, MD, US and Christiane Pott, Kiel, DE	
	<i>Polivalente room, East Campus USI</i>	
14 :00	The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell Lymphoma Daniel J. Hodson, Cambridge, UK	040
14 :15	Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national HOVON trial Martine E.D. Chamuleau, Amsterdam, NL	041
14 :30	Circulating Tumor DNA for Monitoring Primary Mediastinal B-cell Lymphoma in Complement to PET: A Prospective Multicenter LYSA Study Vincent Camus, Rouen, FR	042
14 :45	Circulating tumor DNA sequencing reveals rapid response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma: Molecular insights from the GHSG NIVAHL trial Jan-Michel Heger, Cologne, DE	043
15 :00	Value of end of induction MRD in ctDNA versus peripheral blood/bone marrow for early relapse prediction in advanced follicular lymphoma: a RELEVANCE ancillary study Alexis Claudel, Creteil, FR	044
15 :15	Multi-targeted therapy with ViPOR in mantle cell lymphoma (MCL): Updated analysis of efficacy and minimal residual disease (MRD) Christopher Melani, Bethesda, MD, US	045
15 :45 – 17 :00	PARALLEL SESSIONS 3 parallel sessions	
	<i>Room A, broadcast in Cinema Corso</i>	
	SESSION 7: MANTLE CELL LYMPHOMA Co-chairs: Steven Le Gouill, Paris, FR and Yuqin Song, Beijing, CN	
15 :45	Efficacy of rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk mantle cell lymphoma: An analysis of the phase 3 ECHO trial Martin Dreyling, Munchen, DE	046

16 :00	Ibrutinib and Rituximab is superior to immunochemotherapy in previously untreated mantle cell lymphoma despite lower rates of MRD negativity David Lewis, Plymouth, UK	047
16 :15	Novel Triplet Combination of Orelabrutinib, Lenalidomide, and Rituximab as Frontline Therapy for Mantle Cell Lymphoma: Final Results of POLARIS Multicenter Phase II Study Zheng Song, Tianjin, CN	048
16 :30	Combination Treatment With Novel BCL2 Inhibitor Sonrotoclax (BGB-11417) + Zanubrutinib Induces High Rate of Complete Remission in Relapsed/Refractory Mantle Cell Lymphoma Constantine S. Tam, Melbourne VIC, AU	049
16 :45	Fixed-duration outpatient subcutaneous mosunetuzumab + polatuzumab vedotin shows robust efficacy in a Phase II study of relapsed/refractory post-BTKi mantle cell lymphoma L. Elizabeth Budde, Duarte, CA, US	050
<i>Room B, broadcast in Marquee Parco Ciani</i>	SESSION 8: MARGINAL ZONE AND LYMPHOPLASMACYTIC LYMPHOMAS Co-chairs: Antonio Salar, Barcelona, ES and Ariela Noy, New York, NY, US	
15 :45	Long-term benefit and molecular features of patients with HCV-associated indolent lymphomas treated with direct-acting antivirals: 6-year follow-up of the FIL_BARt study Michele Merli, Milan, IT	051
16 :00	Rituximab and ibrutinib combination is safe and effective in untreated Extranodal Marginal Zone Lymphomas: First analysis of the IELSG47/MALIBU phase II study Annarita Conconi, Biella, IT	052
16 :15	A Phase II Study of Acalabrutinib, Lenalidomide and Rituximab in Patients with Previously Untreated Indolent B-cell Lymphoma Paolo Strati, Houston, TX, US	053
16 :30	Fixed duration treatment of bendamustine-rituximab and acalabrutinib in frontline Waldenström's Macroglobulinemia: deep molecular responses in high-risk patient subsets Neil L. Berinstein, Toronto ON, CA	054
16 :45	Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) marginal zone lymphoma (MZL) in the phase 2 TRANSCEND FL study M. Lia Palomba, New York, NY, US	055
15 :45 – 17 :00 <i>Polivalente room, East Campus USI</i>	SESSION 9: GENOMICS AND CLONAL HEMATOPOIESIS Co-chairs: Elias Campo, Barcelona, ES and Leticia Quintanilla-Martinez, Tübingen, DE	

15 :45	Genomic Analysis of Mature B-cell Lymphomas Ryan D. Morin, Vancouver BC, CA	056
16 :00	CLONAL HEMATOPOIESIS IN FOLLICULAR LYMPHOMA: ANALYSIS OF THE PHASE III FIL FOLL12 TRIAL Riccardo Moia, Novara, IT	057
16 :15	Detection and clinical impact of subclonal TP53 mutations and CHIP in patients with MCL: Results from the EU-MCL network trials Mouhamad Khouja, Kiel, DE	058
16 :30	Clonal hematopoiesis is associated with persisting anemia in elderly patients treated for DLBCL: Analysis of the phase 3 POLAR BEAR trial Simon Husby, Copenhagen, DK	059
16 :45	Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma Deborah Piffaretti, Bellinzona, CH	060
17 :15 – 18 :15	“FOCUS ON...” SESSIONS 5 parallel sessions	
<i>Room A</i>	HODGKIN LYMPHOMA Co-chairs: Alex F. Herrera, Duarte, CA, US and Maria Cristina Piroso, Bellinzona, CH	
17:15	The Early-stage classic Hodgkin Lymphoma International Prognostication Index (E-HIPI): an individualized prediction model utilizing objective and continuous variables Andrew M. Evens, New Brunswick, NJ, US	126
17:25	Health-Related Quality of Life (HRQoL) endpoints of the Phase III Intergroup S1826 Advanced-Stage, Classic Hodgkin Lymphoma (cHL) trial Kelly Davison, Montreal, Quebec ON, CA	127
17:35	Adolescent/ young adult (AYA) patients with high-risk stage 2 classic Hodgkin lymphoma have similar outcomes to stage 3 or 4 with 6 cycles of ABVD chemotherapy Jowon Laura Kim, Vancouver BC, CA	128
17:45	Pembrolizumab and radiation therapy alone as an alternative to transplant for localized failure after chemotherapy in Hodgkin Lymphoma: A multicenter phase II study Alexandra D. Dreyfuss, New York, NY, US	129
17:55	Tislelizumab, an Anti-PD-1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Final Analysis from the LYSA Phase 2 TIRHOL Study BGB-A317-210 Hervé Ghesquières, Pierre Bénite, FR	130

18:05	Improved Outcomes over Time for Relapsed Hodgkin Lymphoma after Autologous and Allogeneic Stem Cell Transplant: From EBMT Lymphoma Working Party Ali Bazarbachi, Beirut, LB	131
<i>Room B</i>	MANTLE CELL LYMPHOMA Co-chairs: Clementine Sarkozy, Lyon, FR and Brad S. Kahl, St. Louis, MO, US	
17:15	Clinical Impact of Clonal and Subclonal Driver Alterations in Mantle Cell Lymphoma Subtypes Cristina López, Barcelona, ES	132
17:25	Long-term Survival Trends in Advanced-Stage Mantle Cell Lymphoma: A Pooled Analysis of Six Randomized Phase III Trials from 1996 to 2020 Eva Hoster, Munich, DE	133
17:35	Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study Michael Wang, Houston, TX, US	134
17:45	Long-Term Follow up of the VALOR (venetoclax, lenalidomide, rituximab) in patients w/ untreated mantle cell lymphoma Tycel Jovelle Phillips, Duarte, CA, US	135
17:55	Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Results from the ECHO trial Pier Luigi Zinzani, Bologna, IT	136
18:05	Ibrutinib added to MCL treatment has strong impact on MRD response and disease kinetics: results from the TRIANGLE trial Mouhamad Khouja, Kiel, DE	137
<i>Cinema Corso</i>	CAR T-CELLS OUTCOMES Co-chairs: Stephen J. Schuster, Philadelphia, PA, US and Catherine Thieblemont, Paris, FR	
17:15	Phase 2 ELARA Trial 4-year Update: Clinical Outcomes of Tisagenlecleucel in Patients (pts) With High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL) Catherine Thieblemont, Paris, FR	138
17:25	Enhanced CAR T-cell Expansion and Durable Complete Responses with NKTR-255 Plus Lisocabtagene Maraleucel in Relapsed/Refractory Large B-cell Lymphoma Alexandre V. Hirayama, Seattle, WA, US	139
17:35	Phase 2 trial of lisocabtagene maraleucel (liso-cel) in combination with acalabrutinib in relapsed/refractory large B-cell lymphomas (LBCL) Patrick C. Johnson, Boston, MA, US	140

17:45	CD30 CAR-T in Relapsed and Refractory CD30+ Lymphomas: Long-Term Follow-Up of a Phase Ib/II Clinical Trial Daniel Reef, Chapel Hill, NC, US	141
17:55	Lisocabtagene maraleucel in R/R FL (TRANSCEND FL): impact of prior lines of therapy, bendamustine exposure, and disease progression \leq24 months of initial systemic therapy Sairah Ahmed, Houston, TX, US	142
18:05	Real-World Outcomes of Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Richter Transformation to Large B-Cell Lymphoma (RT-LBCL) Allison M. Winter, Cleveland, OH, US	143
<i>Auditorium, West Campus USI</i>	EARLY CLINICAL TRIALS Co-chairs: Paola Ghione, New York, NY, US and Franck Morschhauser, Lille, FR	
17:15	Updated Efficacy/Safety of the Bruton Tyrosine Kinase (BTK) Degradar BGB-16673 in Relapsed/Refractory (R/R) CLL/SLL: Results From the Ongoing Phase 1 CaDAnCe-101 Study John F. Seymour, Melbourne VIC, AU	144
17:25	Sonrotoclax (BGB-11417), A Novel BCL2 Inhibitor, Plus Zanubrutinib (Zanu) Demonstrates Deep and Durable Responses in Relapsed/Refractory CLL/SLL: Updated Phase 1 Results Chan Y. Cheah, Nedlands, WA AU	145
17:35	Phase 1/2 Studies of DZD8586 in CLL/SLL Patients after Covalent or Non-covalent BTK Inhibitors and BTK Degraders Jianyong Li, Nanjing, CN	146
17:45	Updated Efficacy & Safety of BTK Degradar BGB-16673 in Patients (Pts) with Relapsed/Refractory Waldenström Macroglobulinemia (R/R WM): Ongoing Phase 1 CaDAnCe-101 Results Anna Maria Frustaci, Milan, IT	147
17:55	Golcadomide \pm Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Phase 1/2 Results Emmanuel Bachy, Lyon, FR	148
18:05	First-in-Human Phase 1 Study of DR-01, a Non-Fucosylated Anti-CD94 Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization Swaminathan P. Iyer, Houston, TX, US	149
<i>Polivalente room, East Campus USI</i>	LIQUID BIOPSY Co-chairs: Vincent Camus, Rouen, FR and Adalgisa Condoluci, Bellinzona, CH	

17:15	Circulating tumour DNA analysis in follicular lymphoma treated with first-line venetoclax, lenalidomide and obinutuzumab on the LEVERAGE trial Chan Cheah, Perth WA, AU	150
17:25	Clinical validity of noninvasive genotyping of MCL at diagnosis from blood plasma by circulating tumor DNA profiling Benoit Tessoulin, Nantes, FR	151
17:35	Glofitamab+R-CHOP in patients with previously untreated large B-cell lymphoma defined as high risk by circulating tumor DNA (ctDNA) dynamics: primary results Marcel Nijland, Groningen, NL	152
17:45	Harnessing systemic inflammation with circulating tumor DNA improves survival prediction in large B-cell lymphoma Sirpa Leppä, Helsinki, FI	153
17:55	CLINICAL IMPACT OF UNTARGETED BASELINE PLASMA METABOLOMICS IN NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA Riccardo Dondolin, Novara, IT	154
18:05	Circulating tumor DNA (ctDNA) for response prediction and genetic characterization of Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) receiving Glofitamab treatment Carmelo Carlo-Stella, Milan, IT	155

08:15 – 09 :00	“MEET THE PROFESSOR” SESSIONS 5 parallel sessions	
<i>Room A</i>	T-cell redirecting therapies (repetition) Gloria Iacoboni, Barcelona, ES	EB7
<i>Room B</i>	Peripheral T-cell lymphoma (repetition) Won Seog Kim, Seoul, KR	EB8
<i>Cinema Corso</i>	Autoimmune complications of lymphoproliferative diseases Wilma Barcellini, Milan, IT	EB1
<i>Auditorium, West Campus USI</i>	Classic Hodgkin lymphoma (repetition) Andrew M. Evens, New Brunswick, NJ, US	EB5
<i>Polivalente room, East Campus USI</i>	Follicular lymphoma (repetition) Jessica Okosun, London, UK	EB10
09 :15 – 10 :30	PARALLEL SESSIONS 5 parallel sessions	
<i>Room A</i>	“CHALLENGING CASES DISCUSSION” SESSION Indolent NHLs and CLL Chair: Jonathan W. Friedberg, Rochester, NY, US Presenter: Adalgisa Condoluci, Bellinzona, CH Discussants: Jonathan Friedberg, Rochester, NY, US, David C. Hodgson, Toronto ON, CA, TBC	
<i>Room B, broadcast in Marquee Parco Ciani</i>	SESSION 10: NK/T-CELL LYMPHOMA Co-chairs: Won Seog Kim, Seoul, KR and Weili Zhao, Shanghai, CN	<u>Abstract nr.</u>
09 :15	A Pivotal Study of SHR2554, An Oral Inhibitor Against Enhancer of Zeste Homolog 2 (EZH2), in Relapsed or Refractory (r/r) Peripheral T-cell Lymphoma (PTCL) Yuqin Song, Beijing, CN	061
09 :30	A Phase II Trial of Pembrolizumab Concurrent with Radiotherapy for Frail Patients with Newly Diagnosed Early-stage Natural Killer/T-cell Lymphoma (IELSG50) Weili Zhao, Shanghai, CN	062

09 :45	Camrelizumab plus low-dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II natural killer/T-cell lymphoma: a multicenter phase II study Chuanxu Liu, Shanghai, CN	063
10 :00	Nivolumab + GemOx as second-line therapy for peripheral T cell lymphoma in transplant-ineligible patients: final analysis of a sub-cohort of the randomized NIVEAU trial Gerhard Held, Leipzig, DE	064
10 :15	Utility of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Extranodal NK/T-cell Lymphoma Ayumi Fujimoto, Tokyo, JP	065
<i>Cinema Corso</i>	“CHALLENGING CASES DISCUSSION” SESSION Difficult Pathological Cases Chair: Elias Campo, Barcelona, ES Presenters: Federico Jauk, Bellinzona, CH Discussants: Stephan Dirnhofer, Basel, CH, Leticia Quintanilla-Martinez, Tübingen, DE	
<i>Polivalente room, East Campus USI</i>	SESSION 11: BASIC AND TRANSLATIONAL RESEARCH (AACR-ICML Joint session) MECHANISMS OF RESISTANCE IN LYMPHOMAS Co-chairs: Margaret A. Shipp, Boston, MA, US and David Scott, Vancouver BC, CA	
09:15	Mechanisms of resistance to checkpoint inhibitors Margaret A. Shipp, Boston, MA, US	066
09:35	Mechanisms of resistance to small molecule inhibitors John F. Seymour, Melbourne VIC, AU	067
09 :55	Mechanisms of resistance to T-cell redirecting therapies Ash A. Alizadeh, Stanford, CA, US	068
10 :15	Escape From CAR-Negative Endogenous CD8 T Cells Drives Resistance to CD19-Directed CAR-T Therapies in Large B-Cell Lymphomas Jonathan H. Schatz, Miami, FL, US	069
09:15 – 12 :00 <i>Auditorium, West Campus USI</i>	LYMPHOMA RADIOTHERAPY WORKSHOP Low doses, few fractions, and new indications for radiation therapy in haematological malignancies Co-chairs: Umberto Ricardi, Turin, IT and Lena Specht, Copenhagen, DK <i>Organised in collaboration with the International Lymphoma Radiation Oncology Group – ILROG</i>	
09:15	The growing use of radiation therapy of multiple myeloma: Looking for clues for better integration with new therapies Alexandra D. Dreyfuss, New York, NY, US	

09:30	Single fraction of 4 Gy for indolent lymphomas – evidence and clinical guidelines Brandon Imber, New York, NY, US	
09:45	Is adjuvant systemic therapy indicated for patients with early-stage indolent lymphomas treated with radiation therapy – immediate vs. deferred treatment Michael MacManus, Melbourne VIC, AU	
10 :00	Response-adapted ultra-low-dose radiation therapy for gastric MALT lymphoma Bouthaina S. Dabaja, Houston, TX, US	
10:15	BREAK	
10:40	Gastric motion and adaptive radiation therapy for gastric lymphoma Peter Meidahl Petersen, Copenhagen, DK	
10:55	Options for consolidation of methotrexate-based response in primary CNS lymphoma – efficacy and safety Kathryn Tringale, La Jolla, CA, US	
11:10	New indications for radiation therapy of mantle cell lymphoma Klaus Herfarth, Heidelberg, DE	
11:25	Few and large fractions (hypofractionation) in modern radiation therapy for haematological malignancies – convenient and safe in selected patients Joanna Yang, St. Louis, MO, US	
11:40	Panel discussion All speakers	
11 :00 – 12 :00	PARALLEL SESSIONS 2 parallel sessions	
<i>Room A, broadcast in Cinema Corso and Polivalente room</i>	SESSION 12: CHRONIC LYMPHOCYTIC LEUKEMIA Co-chairs: Matthew S. Davids, Boston, MA, US and TBC	
11:00	The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-naïve CLL Barbara F. Eichhorst, Cologne, DE	070

11:15	Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study Paolo Ghia, Milan, IT	071
11:30	SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Constantine S. Tam, Melbourne VIC, AU	072
11:45	Primary Endpoint Evaluation of a Multicenter Phase 2 Study of Venetoclax in Combination with R-CHOP (VR-CHOP) for Patients with Richter Syndrome Matthew S. Davids, Boston, MA, US	073
<i>Room B, broadcast in Marquee Parco Ciani</i>	“FOCUS ON...” SESSION DLBCL IN THE ELDERLY Co-chairs: TBC and Maria Gomes da Silva, Lisboa, PT	
11:00	Excellent outcome with interim PET adapted treatment reduction in elderly DLBCL pts with favourable prognosis: Results of 288 pts treated in OPTIMAL>60 of the DSHNHL/GLA Lorenz Thurner, Homburg, DE	156
11:10	PET guided omission of radiotherapy in elderly DLBCL pts with less favourable prognosis is safe: Results of 863 patients treated in the OPTIMAL>60 trial of the DSHNHL/GLA Lorenz Thurner, Homburg, DE	157
11:20	EPCORE DLBCL-3: FIXED-DURATION EPCORITAMAB MONOTHERAPY IN OLDER (≥75 Y), ANTHRACYCLINE-INELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED LARGE B-CELL LYMPHOMA (LBCL) David Belada, Hradec Králové, CZ	158
11:30	R-Pola-Glo – Chemo-light Frontline Therapy Induces High Response Rates with a favorable Safety Profile in Elderly/Frail Patients with Aggressive Lymphoma Rebecca Wurm-Kuczera, Berlin, DE	159
11:40	VERLen: Tafasitamab, Lenalinomide, plus Rituximab in frontline Diffuse Large B-Cell Lymphoma Patients over 80 y/o or older, a LYSA phase 2 trial Benoit Tessoulin, Nantes, FR	160
11:50	Outcomes of Glofitamab and Epcoritamab in R/R DLBCL elderly patients: A Real-World Evidence Study from the CUBIC Consortium Swetha Kambhampati Thiruvengadam, Duarte, CA, US	161

13:00 – 13:45 <i>Room A, broadcast in all rooms</i>	<p>JOHN ULTMANN MEMORIAL LECTURE Chair: Franco Cavalli, Bellinzona, CH <i>Supported by the American Association for Cancer Research – AACR</i></p> <p>Laudatio: T. Andrew Lister, London, UK</p> <p>Extranodal lymphomas: improved outcome through international collaborative research 004 Emanuele Zucca, Bellinzona, CH</p>
14:00 – 15:30	<p>PARALLEL SESSIONS 2 parallel sessions</p>
<i>Room A, broadcast in Cinema Corso</i>	<p>SESSION 13: AGGRESSIVE B-CELL LYMPHOMAS Co-chairs: Weili Zhao, Shanghai, CN and Andy Davies, Southampton, UK</p>
14:00	<p>A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with high-risk diffuse large B-cell lymphoma 074 Jennifer L. Crombie, Boston, MA, US</p>
14:15	<p>Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC and BCL2 Rearrangements with DLBCL Morphology 075 Waleed Alduaij, Vancouver BC, CA</p>
14:30	<p>Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO 076 Jeremy S. Abramson, Boston, MA, US</p>
14:45	<p>Outcomes of CAR T-Cell Therapy Versus Autologous HSCT in Patients with Large B-Cell Lymphoma in Complete Remission: an Analysis from the EBMT Lymphoma Working Party 077 Remy Dulery, Paris, FR</p>
15:00	<p>Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) 078 Juan Pablo Alderuccio, Miami, FL, US</p>
15:15	<p>Outcome of Autologous and Allogenic HCT in Burkitt Lymphoma: An EBMT registry analysis 079 Lorenz Thurner, Homburg, DE</p>
<i>Room B, broadcast in Marquee Parco Ciani</i>	<p>SESSION 14: BIOLOGY OF FOLLICULAR LYMPHOMA Co-chairs: Ryan D. Morin, Vancouver BC, CA and Jessica Okosun, London, UK</p>

14:00	Whole genome sequencing of serial FL biopsies from 96 patients with follicular lymphoma reveal treatment-specific patterns of tumour evolution Laura K. Hilton, Vancouver BC, CA	080
14:15	Repression of miR-29 via MYC Leads to Increased CD40 Signaling in Transformed Follicular Lymphoma (FL) and Unfavourable Prognosis in FL Daniel Filip, Brno, CZ	081
14:30	Characterizing and Targeting Follicular Lymphoma's Common Progenitor Cells Oscar Atkins, London, UK	082
14:45	Single cell analysis reveals extensive immune exhaustion and memory-cell like origin in Follicular Lymphoma (FL) with increased IRF4 expression Patrizia Mondello, Rochester, NY, US	083
15:00	Disrupting follicular dendritic cell interactions and epigenetic regulation to prevent follicular lymphoma progression Wendy Béguelin, New York, NY, US	084
15:15	Patient-Derived lymphoma Spheroids as preclinical models for predicting patient responses to advanced therapies in B-NHL: example of glofitamab in follicular lymphoma Camille Laurent, Toulouse, FR	085
14:00 – 17:00 <i>Auditorium, West Campus USI</i>	SESSION 15: ONCOLOGY NURSING SESSION Chair: Manuela Eicher, Lausanne, CH	
14:00	Delivery of emergency care for patients with lymphoma in a dedicated facility by advanced nurse practitioners Matt Fowler, Derby, UK	ON1
14:30	CART therapy; spotlight on the role of the nurse Maaike E.M. de Ruijter, Amsterdam, NL	ON2
15:00	Protocol for a co-design study exploring experiences of lymphoma patients, informal caregivers, and healthcare professionals with CAR-T therapy Margaret McLauchlan, Lausanne, CH	ON3
15:15	The Experience of Patients with Lymphoma and their Informal Caregivers Related To Chimeric Antigen Receptor T-Cell Therapy: A Qualitative Systematic Review Nina Canova, Lausanne, CH	ON4
15:30	Advancing Nursing Knowledge of CD20-CD3 Bispecific Antibody Treatment for B-cell Non-Hodgkin Lymphoma in Australia: A scoping review of adverse events to inform practice	ON5

Emily Knights, Geelong VIC, AU

15:45	Identifying nursing training needs for the management of bispecific drugs and patient follow-up in onco-hematology units: a non-interventional, e-survey BELL study Mercedes Bou, Valencia, ES	ON6
16:00	Lymphoma care through patients' eyes: findings from the 2023 Swiss Cancer Patient Experiences (SCAPE) survey Chantal Arditi, Lausanne, CH	ON7
16:15	Educational needs of Swiss patients with hematological diseases: focus on knowledge regarding hematology laboratory results and biomedical concepts Claire Dedieu, Lausanne, CH	ON8
16:30	Living with & beyond Lymphoma: Can End Of Treatment (EOT) Nurse-led clinics bridge the gap? Christina Kirby, Basingstoke, UK	ON9
16:45	Development of a Nurse Specialist Role to an Advanced Nurse Practitioner in Lymphoma Care Heather Watson, Derby, UK	ON10
14:30 – 17:00 <i>Polivalente room, East Campus USI</i>	UCLI – ICML JOINT SESSION LYMPHOMA RESEARCH: NEWS FROM CHINA AND EUROPE Honorary co-chairs: Jun Ma, Harbin, CN, Jun Zhu, Beijing, CN, Franco Cavalli, Bellinzona, CH, Julie Vose, Omaha, NE, US Executive co-chairs: Yuqin Song, Beijing, CN, Xiaoqiu Li, Shanghai, CN, Davide Rossi, Bellinzona, CH, Laurence L. de Leval, Lausanne, CH	
14:30	Welcome from the co-chairs	
14:35	Advances in DLBCL Management: Highlights from China Donglu Zhao, Harbin, CN	UCLI1
14:55	State-of-the-art of Liquid Biopsy in Lymphoma Davide Rossi, Bellinzona, CH	UCLI2
15:15	T-cell Lymphoma Treatment: The Chinese Perspective Meng Wu, Beijing, CN	UCLI3
15:35	BREAK	
15:55	Updates in Radiation Therapies in the Treatment of Lymphoma Lena Specht, Copenhagen, DK	UCLI4

16:15	International Overview of Chinese Novel Drugs in Indolent Lymphoma Ou Bai, Changchun, CN	UCL15
16:35	New trends in lymphoma treatment in Western Countries Pier Luigi Zinzani, Bologna, IT	UCL16
16:55	Conclusions remarks by the co-chairs	
15:30 – 15:45 <i>Room A, broadcast in room B, Marquee Parco Ciani, Cinema Corso</i>	Report of the 18-ICML Closed Workshop <i>Speaker to be announced</i>	
15:45 – 17:15 <i>Room A, broadcast in room B, Marquee Parco Ciani, Cinema Corso</i>	SESSION 16: LATE BREAKING ABSTRACTS Co-chairs: Gilles Salles, New York, NY, US and Kim M. Linton, Manchester, UK	
19:00 – 21:00 <i>Cinema Corso</i>	ESMO-ICML Special Joint Event (in-person event only) “Burkitt” documentary film Chair: T. Andrew Lister, London, UK Panel discussion: Martine Chamuleau, Amsterdam, NL, Volker Diehl, Cologne, DE, Éanna Mac Cana, Belfast, UK, Davide Rossi, Bellinzona, CH and Lorna Warwick, Toronto ON, CA	

08:15 – 09:30	SESSION 17: CNS LYMPHOMAS	
<i>Room A,</i>	Co-chairs: TBC	
<i>broadcast in Room</i>		
<i>B</i>		
08:15	EFFICACY OF THIOTEPA-CONDITIONED AUTOLOGOUS TRANSPLANTATION IS INDEPENDENT OF RESPONSE TO HD-MTX-BASED INDUCTION IN PRIMARY CNS LYMPHOMA: EBMT SERIES OF 1,545 PATIENTS	086
	Teresa Calimeri, Milan, IT	
08:30	The PRiZM+ Phase II Platform Study for Relapsed and Refractory Primary CNS Lymphoma: First Results from Cohort 1 Zanubrutinib Monotherapy	087
	Christopher P. Fox, Nottingham, UK	
08:45	Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: efficacy and safety from the phase II PROSPECT study	088
	Lakshmi Nayak, Boston, MA, US	
09:00	Tandem CD20-19-Directed Non-Cryopreserved CAR-T Cells– Zamtocabtagene Autoleucel (Zamto-cel) - in Patients with Relapsed/Refractory CNS Lymphoma in DALY II US study	089
	Patrick B. Johnston, Rochester, MN, US	
09:15	Seven-year follow-up of the IELSG42 “MARIETTA” phase II trial: Durable remissions following MATRix/RICE induction and thiotepa autograft in secondary CNS lymphoma	090
	Kate Cwynarski, London, UK	
09:30 – 10:45	SESSION 18: NEW DRUGS	
<i>Room A</i>	Co-chairs: Anastasios Stathis, Bellinzona, CH and John Kuruvilla, Toronto ON, CA	
09:30	BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader (LDD) of B-cell lymphoma 6 (BCL6) in patients with R/R NHL: Initial Ph 1 results	091
	Franck Morschhauser, Lille, FR	
09:45	E02463 (EO) peptide immunotherapy in combination with lenalidomide (L) and rituximab (R) in patients (pts) with follicular (FL) and marginal zone lymphoma (MZL)	092
	Jose C. Villasboas, Rochester, MN, US	
10:00	Bexobrutideg (NX-5948), a novel BTK degrader, demonstrates rapid and durable clinical responses in relapsed/refractory CLL: updated findings from ongoing Phase 1a study	093
	Alexey Danilov, Duarte, CA, US	

10:15	Safety and Efficacy of AZD0486, a CD19xCD3 T-cell Engager, in Relapsed or Refractory Diffuse Large B-cell Lymphoma Dai Maruyama, Tokyo, JP	094
10:30	A Phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/ refractory non-Hodgkin lymphoma Lugui Qiu, Tianjin CN	095
09:45 – 10:45 <i>Room B</i>	“FOCUS ON” SESSION BIOLOGY AND THERAPY OF T-CELL LYMPHOMAS Co-chairs: Pier Luigi Zinzani, Bologna, IT and Zhi-Ming Li, Guangzhou, CN	
09:45	Pluri-omics characterization establishes monomorphic epitheliotropic intestinal T-cell lymphoma and enteropathy associated T-cell lymphoma as two distinct entities David Vallois, Lausanne, CH	162
09:55	Tazemetostat plus Amdizalisib in Relapsed/Refractory Peripheral T-cell Lymphoma Patients with Diverse Genomic Signatures: Results from a Phase 2 Study Shu Cheng, Shanghai, CN	163
10:05	The Correlation of Mutational Profiles and Valemetostat Efficacy in Patients With R/R PTCL in the Phase 2 VALENTINE-PTCL01 Trial Pier Luigi Zinzani, Bologna, IT	164
10:15	Linperlisib Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma: A Single-Arm, Open-Lable, Multi-Center Phase Ib/II Study (LINCH Trial) Qingqing Cai, Guangzhou, CN	165
10:25	Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Long term follow-up from the TELLOMAK Phase 2 Trial Martine Bagot, Paris, FR	166
10:35	Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with PTCLs after First-line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26) Jie Jin, Hangzhou, CN	167
10:45 – 11:15 <i>Room A, broadcast in Room B</i>	18-ICML HIGHLIGHTS “Take Home Messages” Martin Dreyling, Munich, DE	

11:15 – 11:30

*Room A,
broadcast in Room
B*

CLOSURE AND FAREWELL

Franco Cavalli, Bellinzona, CH

13:30 – 18:00

Room B

VII EUROPEAN LYMPHOMA CANINE NETWORK WORKSHOP

What lies ahead in canine lymphoma therapy?

Steering committee: Barbara Rütgen, Vienna, AT, Sabine E. Hammer, Vienna, AT, Hugo Murua-Escobar, Rostock, DE and Peter Vajdovich, Budapest, HU

Organized by the European Canine Lymphoma Network